Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry

In daily care patients with acute VTE, rivaroxaban demonstrated high effectiveness with acceptable major bleeding rates. Initial dosing was according to label in over 90% of patients and persistence to rivaroxaban therapy was adequate with low rates of unplanned complete discontinuation.